Y-Intercept (HK)
AVBP icon

Y-Intercept (HK)’s ArriVent BioPharma AVBP Stock Holding History

Y-Intercept (HK)’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-11,843
Closed -$411K – 2164
2026
Q2 		$411K Buy
+11,843
New +$350K 0.01% 1366

Other funds holding AVBP

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Moody Aldrich Partners
Moody Aldrich Partners Marblehead, Massachusetts $523M AUM 75.24% 1-Year Est. Return
Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
GF Fund Management
GF Fund Management Guangzhou, China $7.72B AUM 122.96% 1-Year Est. Return
Versant Capital Management
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Y-Intercept (HK)'s AVBP Position: Q3 2026 in Review

Y-Intercept (HK) sold out of ArriVent BioPharma (AVBP) in Q3 2026, closing a stake of 11,843 shares — an estimated $411K sold.

Y-Intercept (HK) first reported a position in AVBP in Q2 2026 and held it in 1 quarter. The position peaked at $411K in Q2 2026. 19 funds tracked by Wall St. Rank hold AVBP as of Q3 2026.

  • Y-Intercept (HK) reported no remaining ArriVent BioPharma position as of Q3 2026 after selling out during the quarter.
  • Y-Intercept (HK) sold 11,843 ArriVent BioPharma shares in Q3 2026, an estimated $411K.
  • Y-Intercept (HK) first reported a position in ArriVent BioPharma in Q2 2026 and held it in 1 quarter.
  • Y-Intercept (HK)'s ArriVent BioPharma position peaked at $411K in Q2 2026.
  • 19 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.